Eli Lillys LLY Shares Surge 157% on $332 Billion Trading Volume as Jaypirca Clinical Triumph Propels 17th Rank and Eyes 60% of $187B CLL Market by 2032

On September 8, 2025, , ranking 17th in market activity. The rally followed the release of promising clinical data for Jaypirca (pirtobrutinib), a non-covalent BTK inhibitor targeting (CLL) and small lymphocytic lymphoma (SLL).

Phase 3 trials demonstrated Jaypirca’s superiority over existing therapies, including , . , aiming to establish it as a first-line treatment. , driven by a differentiated mechanism and cost-reduction programs.

Investor sentiment is further bolstered by Jaypirca’s positioning in a rapidly growing segment. , with first-line therapy representing a key battleground. Eli Lilly’s robust commercial infrastructure and Jaypirca’s safety profile, consistent with prior trials, position it to challenge covalent BTK inhibitors like . Pricing strategies and patient support programs, including a zero-cost option for eligible patients, could accelerate adoption despite competitive pressures.

Back-testing results for a daily-rebalanced portfolio of the top 500 most liquid stocks from January 3, 2022, to present cannot be directly executed due to current system limitations. A single-ticker proxy (e.g., SPY, RSP, QQQ) would approximate the strategy, while a full multi-asset analysis requires external data processing. Investors should clarify their preferred approach for further analysis.